US 8648100
Roflumilast for the treatment of pulmonary hypertension
granted A61KA61K31/44A61K31/4412
Quick answer
US patent 8648100 (Roflumilast for the treatment of pulmonary hypertension) held by TAKEDA GMBH expires Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TAKEDA GMBH
- Grant date
- Tue Feb 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K31/44, A61K31/4412, A61K31/4985, A61K31/5025